FDA Approves Aprepitant Injection for CINV

14:34 EST 28 Feb 2019 | OncLive

The FDA has expanded the approval of aprepitant injectable emulsion to include a 2-minute intravenous use for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.

Original Article: FDA Approves Aprepitant Injection for CINV

More From BioPortfolio on "FDA Approves Aprepitant Injection for CINV"